Understanding and Managing Infusion Reactions and Hypophosphataemia With Intravenous Iron—A Nurses' Consensus Paper [PDF]
Nursing OpenAim To provide evidence‐based guidance on practical aspects and potential safety concerns (infusion reactions and hypophosphataemia) related to the use of intravenous iron from a nursing perspective. Design A modified Delphi consensus method.
Aileen Fraser +5 more
doaj +2 more sources
A Modern‐Day Captain Charles Martell: Catastrophic Skeletal Manifestations of Primary Hyperparathyroidism [PDF]
Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.Primary hyperparathyroidism (PHPT) is characterised by autonomous overproduction of parathyroid hormone (PTH), resulting in hypercalcemia and multisystem complications. Although routine calcium screening has reduced advanced skeletal disease in many regions, severe manifestations such as osteitis fibrosa cystica (OFC) still occur in resource‐limited ...
Rafyat Ara +5 more
wiley +2 more sources
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis. [PDF]
PLoS ONEX-linked hypophosphataemia is a rare, genetic, lifelong disorder caused by phosphate-regulating endopeptidase homologue X-linked pathogenic variants and, if left untreated, is associated with a progressive accumulation of musculoskeletal manifestations ...
Vrinda Saraff +21 more
doaj +2 more sources
Treatment-resistant hypophosphataemia after ferric carboxymaltose: expanding the spectrum of 6H syndrome (hypophosphataemia, hyperphosphaturia, hypovitaminosis D, hypocalcaemia, secondary hyperparathyroidism, high fibroblast growth factor-23) [PDF]
European Journal of Case Reports in Internal MedicineBackground: Ferric carboxymaltose (FCM) is widely used to treat iron deficiency anaemia (IDA), particularly in patients with gastrointestinal disease who are intolerant of oral iron. While generally well tolerated, FCM is increasingly recognised to cause
Luqmaan Rashid
doaj +2 more sources
X‐Linked Hypophosphataemia and Burosumab: A Systemic Disease With a New Treatment [PDF]
Journal of Paediatrics and Child Health, Volume 61, Issue 5, Page 685-700, May 2025.ABSTRACT X linked hypophosphataemia (XLH) is a systemic, chronic condition that significantly impairs quality of life. In XLH, a phosphate regulating endopeptidase homologue X‐linked (PHEX) gene mutation leads to excess fibroblast growth factor 23 (FGF23), causing hypophosphataemia and subsequent rickets, lower limb deformity, pain and other sequelae ...
Jessica L. Sandy +5 more
wiley +2 more sources
Fanconi Syndrome After a Single Exposure to Intravenous Zoledronic Acid [PDF]
Clinical Case Reports, Volume 14, Issue 2, February 2026.ABSTRACT Bisphosphonates are commonly used to reduce fracture risk in patients with osteoporosis, in those with malignant metastatic bone disease and for treatment of malignant hypercalcaemia. We present the case of a woman in her 80s admitted with recurrent falls who developed Fanconi syndrome after a single dose of intravenous Zoledronic acid despite
Rita Deb +2 more
wiley +2 more sources
Hypophosphataemia in a patient with Gitelinan's syndrome [PDF]
Nephrology Dialysis Transplantation, 1996 Gitelman's syndrome, also known as 'hypocalciuric variant' of Bartter's syndrome, is a primary renal tubular disorder characterized by chronic hypokalaemia, hypomagnesaemia, metabolic alkalosis, hypocalciuria with normocalcaemia, hyperreninaemic hyperaldosteronism, and normal renal function [1—3]. The clinical features allowing its differentiation from
Moses Elisaf +2 more
exaly +4 more sources
Intravenous administration of ferric derisomaltose is associated with a higher incidence of infusion reactions than ferric carboxymaltose, and unaffected by dilution volume [PDF]
Internal Medicine Journal, Volume 55, Issue 8, Page 1293-1300, August 2025.Abstract Background The incidence of and risk factors for infusion‐related reactions to intravenous iron formulations remains poorly characterised. This study aimed to compare the rates of infusion reactions in patients receiving ferric derisomaltose (FDI) compared to ferric carboxymaltose (FCM), as well as across different dilutions of FDI.
Sarah Lucas +9 more
wiley +2 more sources
Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART‐FID [PDF]
European Journal of Heart Failure, Volume 27, Issue 5, Page 872-880, May 2025.Changes in serum phosphate levels over time with ferric carboxymaltose (FCM) in a randomized, double‐blind, prospective substudy of HEART‐FID assessing the following outcomes: serum phosphate, 1,25 dihydroxyvitamin D, 25‐hydroxyvitamin D levels and plasma levels of intact parathyroid hormone during 6 months subsequent to FCM infusion.
Nina Nouhravesh +16 more
wiley +2 more sources
A new metabolic path in type 3 rickets [PDF]
The FEBS Journal, Volume 293, Issue 3, Page 656-659, February 2026.Rickets, a bone disorder, was historically categorised into either nutritional (vitamin D deficiency) or genetic forms involving loss‐of‐function mutations in mineral metabolism. Recently, a new mechanism, type 3 rickets, was discovered to be caused by a gain‐of‐function mutation in CYP3A4 (Ile301Thr).
Toshiya Senda, Yoshihisa Hirota
wiley +2 more sources